Followers | 14 |
Posts | 1,650 |
Boards Moderated | 0 |
Alias Born | 11/01/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actually depending on how many shares you own if they do a reverse split you can end up owing money. Etrade charged me a $20 "MANDATORY REORG FEE" recently.
I never heard that about Tuesday/Wednesday. I have heard end of the day Friday is typical for bad news.
today would be nice
Sounds good to me
I just remember how the stock performed after we got the grow license. Regardless we are moving up eventually.
I have a feeling the license is already priced in but I would be happy to be wrong
not if you're taking a loss
looks like by lunch
Innovus (INNV) Licenses Urox Formulation Targeting $3+ Billion Markets -- SECFilings.com
http://analysis.secfilings.com/articles/82-innovus-innv-licenses-urox-formulation-targeting-3-billion-markets
October 20, 2016 8:58 pm ET
Overactive bladder and urinary incontinence affects nearly 60 million Americans in a market that’s worth over $3 billion, according to the Simon Foundation and the National Association for Continence. Innovus Pharmaceuticals Inc. (OTCQB: INNV) aims to tap into the enormous market with a new exclusive licensing deal that it hopes will generate $3 million per year in revenue and bring it closer to bottom-line profitability.
In this article, we will take a closer look at the deal and where the company may be headed over the coming quarters.
Details of the Deal
Innovus Pharmaceuticals Inc. recently announced an exclusive licensing agreement with Seipel Group for the rights to market Urox® formulation to these large end markets. Under the agreement, the clinically proven herbal supplement will be marketed under the UriVarx™ brand name using Innovus’ Beyond Human Sales & Marketing Platform. The team aims to triple the product’s revenue from $1 million in 2015 to $3 million per year.
Urox® is a patented herbal supplement that has been clinically proven to reduce urgency and accidents for patients suffering from overactive bladder and urinary incontinence. In double-blind and comparative trials, researchers found a 56% reduction in urge incontinence, a 66% reduction in stress incontinence, a 61% reduction in urinary urgency, a 33% reduction in urinary frequency, and a 46% reduction in nocturia.
The transaction will make Urox® the 14th product launch for Innovus this year as it builds a robust pipeline of clinically proven over-the-counter supplements and over-the-counter drugs. By offering the product through its Beyond Human Platform reaching 20-30 million people on a monthly basis and to over 1.5 million subscribers, the company aims to generate immediate revenue that will help move it closer to profitability. The company will also leverage its significant reach into publications and retail locations to further drive long-term revenue.
Growing Pipeline
Innovus Pharma has developed a portfolio of over-the-counter products targeting a wide array of different conditions. By leveraging its Beyond Human Platform, the company is able to effectively cross-sell these products to an audience of 20-30 million people on a monthly basis plus the 1.5 million subscribing customers as well as reach new customers through digital and in-person channels. The power of this platform has already been demonstrated by strong sales of its other products like Vesele®, RecalMax™ and Sensum+®.
In addition to this growing portfolio, the company’s FlutiCare™ product is pending ANDA approval from the FDA. If approved, the company will own an over-the-counter version of a leading prescription drug targeting the multi-billion-dollar allergy relief industry where millions of sufferers are in need of better solutions. The FDA decision is expected to be before the end of the year and could be a large potential catalyst for the stock.
The company differentiates itself from many other nutraceutical or botanical companies with its clinically proven products that have already achieved product-market fit. For example, Vesele® enhances blood flow and promotes sexual health, Zestra® boosts female arousal, EjectDelay® addresses premature ejaculation, and RecalMax™ improves cognitive function. All of these products have benefited from the robust Beyond Human marketing platform.
Looking Ahead
Innovus Pharmaceuticals, Inc. represents a compelling opportunity to invest in an early-stage pharmaceutical company that’s seeing strong revenue growth and is on track to become profitable over the near-term. With a market capitalization of approximately $25 million, the market may be undervaluing the stock based on its existing revenue, while discounting new product launches, revenue streams, and the potential for its FlutiCare™ ANDA coming down the road.
Investors may want to consider the micro-cap company for the speculative portion of their portfolios as a potentially high growth opportunity with numerous catalysts.
For more information, visit the company’s website at www.innovuspharma.com or learn more on SECFilings.com at http://analysis.secfilings.com/companies/4-innovus-pharmaceuticals-inc.
I think the drop is due to people anticipating the sell license. Maybe got tired of waiting but I'm still up more than a 100% from holding earlier. I wanted an opportunity to load more.
We are below the levels I've been loading the past year so I'm not thrilled
I don't think uplisting is a priority right now
I think there is slim chances of no panic selling
A publicly held company may deregister its equity securities when they are held by less than 300 shareholders of record or less than 500 shareholders of record, where the company does not have significant assets. Depending on the facts and circumstances, the company may no longer be required to file periodic reports with the SEC once the number of shareholders of record drops below the above thresholds.
A number of kinds of transactions can result in a company going private, including:
Another company or individual makes a tender offer to buy all or most of the company’s publicly held shares;
The company merges with or sells all or substantially all of the company’s assets to another company; or
The company declares a reverse stock split that reduces the number of shareholders of record. In a reverse stock split, the company typically gives shareholders a single new share in exchange for a block—10, 100, or even 1,000 shares—of the old shares. If a shareholder does not have a sufficient number of old shares to exchange for new shares, the company will usually pay the shareholder cash instead of issuing a new share, thus eliminating some smaller shareholders of record and reducing the total number of shareholders.
Zacks Investment Research has downgraded Innovus Pharmaceuticals Inc (NASDAQ:INNV) to Hold in a report released on 10/17/2016.
http://breakingfinancenews.com/investing/innovus-pharmaceuticals-inc-nasdaqinnv-has-been-downgraded-to-hold-in-a-report-by-zacks-investment-research-today/77904/
Previously on Wednesday August 17, 2016, Zacks Investment Research reported on Innovus Pharmaceuticals Inc (NASDAQ:INNV) increased the target price from $0.00 to $0.50 that suggested an upside of 0.09%.
Yesterday Innovus Pharmaceuticals Inc (NASDAQ:INNV) traded -6.47% lower at $0.27. The company’s 50-day moving average is $0.29 and its 200-day moving average is $0.26. The last stock close price is up 4.70% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 538,025 shares of Innovus Pharmaceuticals Inc exchanged hands, down from an avg. volume of 1,285,300
With a total market value of $0, Innovus Pharmaceuticals Inc has with a 52 week low of $0.03 and a 52 week high of $0.66 .
General Information About Innovus Pharmaceuticals Inc (NASDAQ:INNV)
Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.
I think it can help bring in new investors
*Rate is the change in posting activity in the past 24 hours vs. the average from the prior 7 days
** Market data is delayed 15-20 minutes and is updated once per minute.
*** The number of IH top 50 most followed members posting in the last 24 hours.
I think it's mostly due to how much people post on the message board. If you have an average of five or ten posts per day but then suddenly have 30-50 posts in a day you are trending.
That run was due to a promo IMO
allegedly
My guess is he didn't read the first part of that sentence:
"Once FlutiCare™ "can be bought without a prescription,"
Looks like it.
https://ceocfointerviews.com/
It would help to post it but nothing new here. Maybe it might bring more investors.
Dr. Bassam Damaj of Innovus Pharma: Rapid Growth Plan Succeeds
https://finance.yahoo.com/news/dr-bassam-damaj-innovus-pharma-133000736.html
SAN DIEGO CA--(Marketwired - Oct 11, 2016) - Innovus Pharma ( OTCQB : INNV ) is one of those very rare microcap companies with real products, real revenues, and a proven record of rapid growth, according to a new updated analysis by CEOCFO magazine.
CEOCFO states that the San Diego-based consumer and pharmaceutical company pulled in more than $1 million product sales in the second quarter of 2016, an increase of over 400% compared to the first quarter of 2016. It's on track for more than $5 million in revenues for all of 2016 -- and $15 million in 2017, which would put Innovus Pharmaceuticals, Inc. ( OTCQB : INNV ) firmly in the black. Most important, the Company has acquired the worldwide rights to FlutiCare™, a nasal spray for allergy symptoms that Innovus will market over-the-counter (OTC).
"We believe there is incredible potential here," the Biotech Stock Review writes. Once FlutiCare™ "can be bought without a prescription, the overall market could expand to 77 million units (per year) or over $1 billion in sales."
"People have been surprised at the significant revenue growth," says CEO Dr. Bassam Damaj. "And with key mainstream drugs like FlutiCare™, the real growth is just starting," Damaj adds. "Our goal is to up-list to the NASDAQ exchange at the right time and grow to be a significant revenue-generating Company with earnings."
The secret of Innovus' success is conceptually simple: Acquire products that bring real benefits to patients and that already have strong revenues or have revenue potential, and sell them under the proprietary Beyond Human sales and marketing platform.
But that's easier said than done. It takes an experienced biotech and pharma chief executive like the Lebanese-born Damaj, 47, who trained at and has helped bring drugs to market at such major companies as Pfizer, Genentech, Pharmacopeia, Tanabe Seiyaku (now Mitsubishi-Tanabe) and Apricus Biosciences. "This is what I do best," he explains. "I'm very well known in the field, so I know what's out there, what will succeed in the marketplace, and what will make a difference in the lives of people."
It also helped that Damaj brought $2.5 million of his own money to the Company when he joined the Company in 2013, and has been able to raise $5 million more this year on the strength of his reputation for spotting the growth potential in products when others don't.
The money has enabled Innovus to acquire several moneymaking products in a broad range of areas, such as sexual health, vitality, vision, urology, and allergy relief. All are backed up by patent protection or proprietary formulations, and supported by clinical data; more are on the way.
One of the most successful purchases for Innovus was acquiring supplement company Beyond Human and its powerful marketing and sales platform. Beyond Human's lead product, BTH® Testosterone Booster, is a dietary supplement containing vitamins, zinc, and extracts of the herbs fenugreek and Eurycoma longifolia, which have been linked to increased testosterone levels and enhanced sexual function. That product had sales of $2.2 million in 2015 and is bringing significant revenues for Innovus, says Damaj.
Another top seller is Vesele®, a supplement that enhances blood flow and promotes both sexual health, as shown in a clinical use survey trial, Damaj says. Innovus acquired the product for $40,000 in 2015 and now it is the best-selling product for Company.
Strong clinical trials and patents also support Zestra®, a blend of oils that boosts female arousal, which Innovus acquired from Semprae Laboratories, Inc. In addition, Innovus's product lineup includes EjectDelay® for premature ejaculation, Androferti® (in the US and Canada) for overall male reproductive health and sperm quality, and BTH Vision Formula.
But both Damaj and investors are particularly excited by Innovus's 2015 merger with Novalere FP, which brought to Innovus the worldwide rights to the FlutiCare™ brand.
Fluticare™ (containing the active pharmaceutical product fluticasone propionate nasal spray) is a type of corticosteroid used to fight symptoms of allergies, such as stuffy and runny noses, itching, and sneezing -- and is a key product in the $1 billion annual market for nasal steroids. FlutiCare™ now is a prescription generic version of the top-selling brand-name drug Flonase, but is expected to go OTC by the end of 2016. "FlutiCare™ will put us on the map as an important mainstream pharmaceutical company," says Damaj.
Maybe he is just a name holding a title. I wonder how often he is in office.
I actually sold a lot of shares and then started buying dips. Didn't expect us to go this low.
I wouldn't be surprised
tomorrow would be nice
sucks to be back at these levels
Innovus Pharma Initiates Pre-Clinical and Clinical Program Evaluating the Safety and Efficacy of Vesele® with Sildenafil (Viagra®)
http://www.businesswire.com/news/home/20161005005314/en/Innovus-Pharma-Initiates-Pre-Clinical-Clinical-Program-Evaluating
October 05, 2016 06:00 AM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men’s and women's health and respiratory diseases, announced today the initiation of a pre-clinical and clinical program intended to evaluate the safety and efficacy of the combination of its supplement Vesele® for promoting sexual health with sildenafil indicated for treating erectile dysfunction. Sildenafil in the U.S. is sold under the name Viagra® by Pfizer, Inc. (“Pfizer”).
Vesele® is a proprietary oral formulation of L-Arginine and L-Citrulline with the natural absorption enhancer Bioperine®. Vesele® was formulated to increase blood flow and nitric oxide production.
As previously reported, the Company performed a U.S. human clinical survey to evaluate erectile dysfunction and sexual satisfaction in men using Vesele® twice daily for up to four months with the following favorable results:
1. 49.5% increase in erection hardness;
2. 44.5% increase in erection maintenance;
3. 34.6% increase in desire for sexual activity; and
4. 34.1% increase in the ability to satisfy the partner.
“Due to the positive results obtained on the erection hardness and maintenance in the clinical use survey with Vesele® and the complimentary mechanism of action of Vesele® on nitric oxide and blood flow, we believe it is only natural to evaluate the effects of the combination of both products on erectile dysfunction endpoints,” said Innovus CEO Dr. Bassam Damaj.
The open label, single arm study is designed to assess the safety and effect of concomitant use of Vesele® and sildenafil in men diagnosed with erectile dysfunction. The treatment consists of oral administration of Vesele® twice daily (BID) for four weeks and sildenafil 100 mg taken concurrently once weekly. Safety will be evaluated by the number of subjects experiencing adverse events and changes in safety parameters that include physical examination, clinical lab tests, and concomitant medication usage. The IIEF (International Index of Erectile Function), a multi-dimensional, validated diagnostic tool will be used to assess erectile function and treatment outcomes.
About Vesele®
Vesele® is a proprietary, novel oral dietary supplement to maximize nitric oxide’s beneficial effects on sexual function and brain health. Vesele® contains a patented formulation of L-Arginine and L-Citrulline, in combination with the natural absorption enhancer Bioperine®. For more information on Vesele® please visit www.myvesele.com.
Viagra® is a trademark owned by Pfizer.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for men's and women's health and respiratory diseases. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® to help with reduced penile sensitivity, (f) Zestra Glide®, (g)Vesele® for promoting sexual health, (h) RecalMax™ for promoting brain and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for allergic rhinitis, if its ANDA is approved by the U.S. FDA.
For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.urivarx.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, results from the above pre-clinical and clinical trial, projected revenues, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.
Contacts
Chesapeake Group
Kevin Holmes, 410-825-3930
info@chesapeakegp.com
Canadian Cannabis Stocks Spike Up As Marijuana Operations Expand With Innovative Technology
http://www.wdrb.com/story/33321254/canadian-cannabis-stocks-spike-up-as-marijuana-operations-expand-with-innovative-technology
and on the way to $1+
A Close Look at Innovus Pharmaceuticals Inc (OTCMKTS:INNV)
http://www.microcapdaily.com/a-close-look-at-innovus-pharmaceuticals-inc-otcmktsinnv/116745/
BY DAVE YOUNG ON OCTOBER 3, 2016 MICRO CAP INSIDER, STREET WATCH
Innovus Pharmaceuticals Inc (OTCMKTS:INNV) has formed a strong base at the $0.30 level in recent weeks after topping out at $0.663 in July. The stock was trading for as little as $0.028 8 months ago.
There is plenty to get excited about on INNV who recently announced their intention to up-list to the NYSE. INNV already owns an extensive portfolio of over-the-counter (OTC) brands that could become billion dollar revenue streams. They are also waiting to hear back from the FDA on their New Drug Application (ANDA) for FlutiCare that sold more than 177 million units in its RX form.
Innovus Pharmaceuticals Inc (OTCMKTS:INNV) is an emerging leader in OTC and consumer products for men’s and women’s health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
INNV has established significant distribution channels in the US through Walmart, Target, Walgreen’s Drugstore.com, and many other known retailers. The company’s largest target market is allergic and non-allergic rhinitis – better known as “hay fever” or “stuffy nose” by the general public. The company’s FlutiCare™ active is the #1 nasal steroid prescribed by physicians and used by patients. After dispensing more than 177 million units since 2007, Innovus is seeking to secure an Abbreviated New Drug Application from the FDA to launch an over-the-counter option for those seeking relief from rhinitis symptoms. According to a report by Fierce Pharma, GSK’s Flonase OTC sold over $100,000M in a short period of time from its launch confirming the size of the market and the potential of FlutiCare™ if approved.
Female sexual dysfunction is the second market. The condition affects approximately 43% of women, compared to just 31% of men reporting similar difficulties. Whereas erectile dysfunction has become a $6 billion market, INNV’s Zestra® is the only clinically proven, commercially sold consumer care product with statistical significance in addressing these issues for women. The company has sold more than 12.5 million doses sold to date.
One of the exciting aspects of INNV is FlutiCare, the leading nasal steroid recommended by physicians for the treatment of nasal congestion, sneezing, runny nose, and itchy nose which sold more than 177 million units in its RX form. The Company acquired the over-the-counter rights to FlutiCare early last year has been making its way through the lengthy approval process with the FDA.
INNV filed the over-the-counter Abbreviated New Drug Application (ANDA) for FlutiCare during the fourth quarter of 2014 which was accepted by the FDA for review. According to many sources the Company should hear back from the FDA on the ANDA within the next two months.
On October 3 INNV announced an exclusive licensing agreement with Seipel Group (SG) for the rights to market Urox® Formulation using the Company’s Beyond Human Platform.
Urox® is a specialized patented herbal supplement. It has been clinically proven to reduce urinary urgency, accidents and both day and night frequency in Overactive Bladder (OAB) and Urinary Incontinence (UI) patients. Innovus will market the product under the name UriVaRx™ using its Beyond Human Platform.
Under the exclusive agreement, Innovus Pharma will pay SG an upfront payment and will commit to a yearly supply of product. Innovus Pharma’s marketing goal is to triple the sales of the supplement from $1 million in 2015 to close to $3 million per year. Urox® has undergone multiple double blind and comparative trials in both male and female OAB and UI patients.
Currently trading at a $27 million market valuation INNV had $8 million in debt, little assets and small but growing revenues. INVV is an exciting story in small caps; the Company already owns an extensive portfolio of over-the-counter (OTC) brands that could become billion dollar revenue streams. They also have established distribution channels through Walmart, Target, and Walgreen’s Drugstore.com and recently announced their intention to up-list to the NYSE. INNV is waiting to hear back from the FDA on their New Drug Application (ANDA) for FlutiCare that sold more than 177 million units in its RX form.
Disclosure: we hold no position in INNV either long or short and we have not been compensated for this article.
People are locked into Fluticare for some reason. This will likely cause a huge drop at the end of the month.
I'm just surprised there is no interim update on revenues (that bothers me).
During the second quarter, the company reported a 455% increase in revenue to a record $1 million with $256,000 in operating cash flow. Management stated that the company is on track to reach $5 million in revenue for the full year of 2016 -- and that doesn't include any revenues from FlutiCare™ or other high-profile upcoming product launches.
Management anticipates that these two products will add an additional $3 million to $4 million in revenue on a yearly basis provided that they are successfully launched on the Beyond Human platform.
Innovus Pharmaceuticals projects earnings $5 million in 2016 based on its existing launched product lines. If management is successful in launching two new products, these revenues could expand by around $1 million in the remainder of the year.
The company’s stock trades with a market capitalization of just $21 million, according to OTC Markets. This would put its price-sales ratio at just 4x – less than many competitors in the space – with a significant double- to triple-digit growth rate.
I figure they probably go security in there and don't allow walk-ins
I next to a FDA office and I wish I could run in there and start asking questions.
and there's the dip
Fluticare is only part of the company. If we don't get an approval soon a drop would only be temporary if it even happens.
Innovus (INNV) Beyond Human Platform, Reaching Between 20-30 Million People On A Monthly Basis, Propels High Margin Sales
http://analysis.secfilings.com/articles/66-innovus-innv-beyond-human-platform-reaching-between-20-30-million-people-on-a-monthly-basis-propels-high-margin-sales
By RYAN ALLWAY
September 19, 2016 1:23 pm ET
Innovus Pharmaceuticals Inc. (OTCQB: INNV) acquired Beyond Human LLC in February for $630,000 in cash and the deal is already paying big dividends. During the second quarter, the company reported a 455% increase in revenue to a record $1 million with $256,000 in operating cash flow. Management stated that the company is on track to reach $5 million in revenue for the full year of 2016 – and that doesn’t include any revenues from FlutiCare™ or other high-profile upcoming product launches.
In this article, we will take a closer look at why Beyond Human has become the cornerstone for the company’s ongoing success and why investors should take a closer look at the stock.
Acquiring More than Products
Innovus Pharmaceuticals gained more than just a handful of successful products with the acquisition of Beyond Human – they gained access to a print media network reaching between 20-30 million people on a monthly basis in the U.S. Innovus also gained a very large number of online email subscribers, pushing the company's total number of subscribers to about 1.5 million people.
The company’s marketing team develops editorial content that is pushed through the platform’s distribution channels to drive inbound sales calls. A 75-person call center takes care of inbound sales and upsells customers on additional products. For example, a person that calls to purchase the Beyond Human Testosterone Booster might also order Vesele®, since it’s a complementary product for that particular demographic.
Vesele® is a great example of why the marketing platform has become so important to Innovus Pharma. After acquiring the product from Trophikos for $40,000 in 2014, the company re-launched the product on the Beyond Human platform and has already generated the bulk of the $1M reported in Q2 2016 along with the testosterone booster product. These revenues also contributed to higher profit margins of 68% in 2016 compared to 58% in 2015 since there are fewer overhead costs and third parties involved in the sales process. The company announced the launch of a third product, RecalMax™, on the same platform few weeks ago and per the company’s presentation at the Rodman & Renshaw Conference in New York on September 12, 2016, the product is selling very well and is on track to being another large product for Innovus.
Platform for Future Growth
Innovus Pharmaceuticals plans to launch several new products using the Beyond Human platform over the coming quarters. Moreover, these product launches have not been factored into management’s $5 million 2016 revenue projection.
CEO Dr. Bassam Damaj indicated that the company plans on launching Sensum+® for penile sensitivity and Xyralid® for hemorrhoids throughout the remainder of the year in its second quarter conference call. Management anticipates that these two products will add an additional $3 million to $4 million in revenue on a yearly basis provided that they are successfully launched on the Beyond Human platform.
The company also has not factored in the potential approval and launch of FlutiCare™ as an over-the-counter treatment for non-allergic rhinitis – or stuffy nose. With over 50 million American affected by the condition each year and 70% of those using over-the-counter products dissatisfied, there’s an enormous opportunity for the #1 form of the prescribed nasal steroid to make a big splash in the OTC market.
FlutiCare™ could be marketed through the same Beyond Human platform in order to increase sales and improve margins by adding to the traditional retail route as the demographic and the people targeted with the platform are unique and differ from the traditional people who shop from the usual retail stores. The combination of 70%+ gross margins and a massive market size – as suggested by the competitor Flonase’s blockbuster status – could translate to significant shareholder value creation over the coming years.
Looking Ahead
Innovus Pharmaceuticals projects earnings $5 million in 2016 based on its existing launched product lines. If management is successful in launching two new products, these revenues could expand by around $1 million in the remainder of the year. The approval of FlutiCare™ could further expand these revenues if it were commercialized before year-end. And, all of these products benefit from distribution on the well-established Beyond Human platform.
The company’s stock trades with a market capitalization of just $21 million, according to OTC Markets. This would put its price-sales ratio at just 4x – less than many competitors in the space – with a significant double- to triple-digit growth rate. Investors may want to take a closer look at the stock given this potential, as well as the numerous upcoming catalysts in the form of a possible ANDA approval for FlutiCare™ and upcoming product launches.
For more information, visit the company’s website at www.innovuspharma.com.